Clinical Trial Update: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating PLX 3397 in combination with eribulin for metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• PLX 3397

Snippet

Sponsor: Hope Rugo, MD | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-14